• Budesonide respiratory suspension is indicated for maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age.
• Budesonide tablet is indicated for treatment of mild to moderate ulcerative colitis.

Asthma

Ulcerative Colitis

Therapy should start with the lowest recommended dose: 

• Bronchodilators alone: 0.5 mg once daily or 0.25 mg twice daily 
• Inhaled corticosteroids: 0.5 mg once daily or 0.25 mg twice daily up to 0.5 mg twice daily
• Oral corticosteroids: 0.5 mg twice daily or 1 mg once daily 
• In symptomatic children not responding to non-steroidal therapy, a starting dose of 0.25 mg once daily may be considered 
• If once-daily treatment does not provide adequate control, the total daily dose should be increased and/or administered as a divided dose. Once asthma stability is achieved, titrate the dose downwards 
• For inhalation use via compressed air driven jet nebulizers only (not for use with ultrasonic devices). 

Most common adverse reactions (incidence >3%) are-

• respiratory infection
• rhinitis
• coughing
• otitis media
• viral infection
• moniliasis
• gastroenteritis
• vomiting
• diarrhea
• abdominal pain
• ear infection
• epistaxis
• conjunctivitis
• rash

Respiratory infections	Rhinitis	Coughing	Otitis
Viral Infection	Vomiting	Diarrhea	Abdominal Pain

• Localized Infections: Candida albicans infection of the mouth and throat may occur. Monitor patients periodically for signs of adverse effects on the oral cavity. Advise patients to rinse the mouth following inhalation.
• Deterioration of Disease and Acute Asthma Episodes: Do not use for the relief of acute bronchospasm.
• • Hypersensitivity Reactions: Anaphylaxis, rash, contact dermatitis, urticaria, angioedema, and bronchospasm have been reported with use of Budesonide respiratory capsules. Discontinue Budesonide respiratory capsules if such reactions occur 
• Immunosuppression: Potential worsening of infections (e.g., existing tuberculosis, fungal, bacterial, viral, or parasitic infection; or ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients
• Transferring Patients from Systemic Corticosteroid Therapy: Risk of impaired adrenal function when transferring from oral steroids. Taper patients slowly from systemic corticosteroids if transferring to Budesonide respiratory capsules 
• Hypercorticism and Adrenal Suppression: May occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, reduce Budesonide respiratory capsules slowly 
• Reduction in Bone Mineral Density with Long-term Administration: Monitor patients with major risk factors for decreased bone mineral content (5.7) • Effects on Growth: Monitor growth of pediatric patients 
• Glaucoma and Cataracts: Close monitoring is warranted 
• Paradoxical Bronchospasm: Discontinue Budesonide respiratory capsules and institute alternative therapy if paradoxical bronchospasm occurs 
• Eosinophilic Conditions and Churg-Strauss Syndrome: Be alert to eosinophilic conditions